Cumberland Pharmaceuticals (CPIX) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cumberland Pharmaceuticals (CPIX) has outperformed Zhengye Biotechnology (ZYBT) over the past year, gaining 90.2% versus a loss of 62.7%. Cumberland Pharmaceuticals is the larger company by market cap ($104.6 million vs $54.5 million), about 1.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPIX | ZYBT |
|---|---|---|
| Share price | $6.98 | $1.15 |
| Market cap | $104.58M | $54.50M |
| 1-day change | +1.31% | -0.87% |
| YTD return | +75.38% | -0.01% |
| 1-year return | +90.19% | -62.67% |
| 5-year return | +154.74% | — |
| Forward P/E | 49.86 | — |
| EPS (TTM) | $-0.62 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.28 | $8.01 |
| 52-week low | $1.85 | $0.616 |
| Distance from 52-week high | -24.78% | -85.64% |
| Average volume | 87.71K | 5.11M |
| Shares outstanding | 14.98M | 47.39M |
| Employees | 88 | 269 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CPIX has outperformed ZYBT by 152.9 percentage points over the past year.
About Cumberland Pharmaceuticals
CPIX stock →Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
Healthcare · Drug Manufacturers - Specialty & Generic · 88 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Healthcare · Drug Manufacturers - Specialty & Generic · 269 employees
CPIX vs ZYBT FAQ
Which is bigger, Cumberland Pharmaceuticals or Zhengye Biotechnology?
Cumberland Pharmaceuticals (CPIX) is larger, with a market capitalization of $104.58M compared with $54.50M for Zhengye Biotechnology (ZYBT).
Which stock has performed better over the past year, CPIX or ZYBT?
CPIX returned +90.19% over the past 12 months, compared with -62.67% for ZYBT (price return, excluding dividends). Past performance does not predict future results.
Are Cumberland Pharmaceuticals and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.